Melissa Slogan

Welcome to the thirteenth issue of our report, “Mpox: Transparency and Accountability for the Global Response.” In the wake of the U.S. health agencies’ communications and foreign aid freezes, we hope to serve as a resource for transparency on emerging outbreaks globally while continuing to provide in-depth analysis of the mpox response. We will provide brief updates on emerging outbreaks with the state of available medical countermeasures and diagnostics needed to effectively respond. The intensification phase of the response appears to have an impact with an observed decline in suspected and confirmed cases: There has been a decrease in the average weekly case counts for both confirmed and suspected mpox cases across the continent in the last 6 weeks when compared to the first 6 weeks following the PHECS declaration in…

This newsletter aims to provide a central hub for information, milestones, and updates regarding the COVID Treatment QuickStart Consortium. The COVID Treatment QuickStart Consortium partners with governments to rapidly introduce and scale access to COVID-19 oral antiviral therapies in vulnerable and high-risk populations presenting with mild to moderate symptoms within five days of symptom onset through a public health test-and-treat model. QuickStart’s top priorities are: Ensuring treatments are accessible in all parts of the world; Preparing for potential future COVID-19 surges; and Building primary healthcare capacity for test-and-treat beyond COVID-19. View the April 2025 QuickStart newsletter. Subscribe to the QuickStart newsletter.

This newsletter aims to provide a central hub for information, milestones, and updates regarding the COVID Treatment QuickStart Consortium. The COVID Treatment QuickStart Consortium partners with governments to rapidly introduce and scale access to COVID-19 oral antiviral therapies in vulnerable and high-risk populations presenting with mild to moderate symptoms within five days of symptom onset through a public health test-and-treat model. QuickStart’s top priorities are: Ensuring treatments are accessible in all parts of the world; Preparing for potential future COVID-19 surges; and Building primary healthcare capacity for test-and-treat beyond COVID-19. View the December 2024 QuickStart newsletter. Subscribe to the QuickStart newsletter.